BCR-ABL-IN-1

BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl

Research Areas >> Cancer

pIC50: 6.46 (BCR-ABL)[1]

BCR-ABL-IN-1 (Compound 21) is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.

[1]. Cui J1, et al. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2442-50.

Nocodazole | Asciminib | Degrasyn(WP1130) | Bafetinib (INNO-406) | DCC-2036 (Rebastinib) | KW-2449 | AST 487 | PD173955 | XL228 | DPH | GNF-2 | GNF-7 | GZD824 | Flumatinib | GNF-5